QNRX insider transaction filings
Quoin Pharmaceuticals, Ltd. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-31. Screen QNRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-31 | 4 | Stonepine Capital Management, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-02-06 | 4 | Lawlor Sally Bridget — Chief Financial Officer | Grant/award (A): 85,250 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Culverwell Anthony James — Director | Grant/award (A): 21,709 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Myers Michael — Chief Executive Officer, Director | Grant/award (A): 318,750 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Carter Denise P. — Chief Operating Officer, Director | Grant/award (A): 318,750 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Leong Natalie Ee Mun — Director | Grant/award (A): 12,211 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Cooper Joseph Patrick — Director | Grant/award (A): 8,141 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | LANGER DENNIS — Director | Grant/award (A): 21,709 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | SEMBER MICHAEL T — Director | Grant/award (A): 8,141 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Lawlor Sally Bridget — Chief Financial Officer | Grant/award (A): 10,330 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | LANGER DENNIS — Director | Purchase (P): 15,152 @ $8.49 · Purchase (P): 15,152 (derivative) · Purchase (P): 15,152 (derivative) · Purchase (P): 15,152 (derivative) · Purchase (P): 15,152 (derivative) | EDGAR |
| 2025-08-25 | 4 | Leong Natalie Ee Mun — Director | Grant/award (A): 4,105 (derivative) @ $0 | EDGAR |
| 2025-08-25 | 4 | Culverwell Anthony James — Director | Grant/award (A): 13,682 (derivative) @ $0 | EDGAR |
| 2025-08-25 | 4 | LANGER DENNIS — Director | Grant/award (A): 13,682 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4/A | Carter Denise P. — Chief Operating Officer, Director | Grant/award (A): 42,857 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4/A | Myers Michael — Chief Executive Officer, Director | Grant/award (A): 42,857 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Culverwell Anthony James — Director | Grant/award (A): 7,760 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Myers Michael — Chief Executive Officer, Director | Grant/award (A): 42,039 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Carter Denise P. — Chief Operating Officer, Director | Grant/award (A): 42,039 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Leong Natalie Ee Mun — Director | Grant/award (A): 7,760 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Cooper Joseph Patrick — Director | Grant/award (A): 7,760 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | LANGER DENNIS — Director | Grant/award (A): 7,760 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | SEMBER MICHAEL T — Director | Grant/award (A): 7,760 (derivative) @ $0 | EDGAR |
Recent 8-K events — Quoin Pharmaceuticals, Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=QNRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →